PFIZER INC Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
PFIZER INC (PFE) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $2.26 billion as of 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-08-04
- 2026-06-28: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $2.26B.
- 2026-03-29: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $2.04B.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $1.79B.
- 2025-06-29: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $508.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2026-06-28 | $2.26B 10-Q · filed 2026-08-04 |
| 2026-03-29 | $2.04B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $1.79B 10-Q · filed 2026-08-04 |
| 2025-06-29 | $508.00M 10-Q · filed 2026-08-04 |
| 2025-03-30 | $477.00M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $517.00M 10-Q · filed 2026-08-04 |
| 2023-12-31 | $692.00M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |